Clinical Trial

MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma

Study acronym: CAREMM-007
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of the BCMA/CD3 bispecific antibody (CM336) as maintenance therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-08
Trial Details
NCT Number NCT07409454
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Multiple Myeloma
Enrollment 20 participants
Start Date 2026-07-07
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-07